The purpose of this study is to investigate the efficacy and mechanism of Adipokines Cardiac Protection in Obese Patients With coronary artery disease (CAD).
Adipokines (or adipocytokines) can be defined as a group of more than 600 bioactive molecules made from adipose tissue that acts as paracrine and endocrine hormones. Adipokines are involved in maintaining varieties of processes such as, appetite and satiety, energy expenditure activity, endothelial function, blood pressure, hemostasis, adipogenesis, insulin sensitivity, energy metabolism in insulin-sensitive tissues, fat distribution and insulin secretion in pancreatic β-cells. Adipokines may contribute to reduce scar formation and improve cardiac function in coronary artery disease (CAD). Reperfusion therapy such as percutaneous coronary intervention (PCI) should be administered to all eligible patients with CAD symptom. However, our previous work showed that obese patients may benefit more from PCI. Thus, the aim of the present study was to investigate the efficacy and mechanism of adipokines cardiac protection for obese and non-obese patients with coronary artery disease (CAD).
Study Type
OBSERVATIONAL
Enrollment
200
percutaneous coronary intervention
Xijing hospital
Xi'an, Shaanxi, China
RECRUITINGNumber of patient death during the follow up period
Time frame: 1 year
Left ventricular ejection fraction
Time frame: 1 year
Number of target vessel revascularization
Time frame: 1 year
Angina class according to the canadian cardiovascular society (CCS) classification
Time frame: 1 year
Scores on the Seattle angina questionnaire
Time frame: 1 year
six-min walk distance (6MWD)
Time frame: 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.